speed and severity of improvement of peripheral vertigo in the group treated with promethazine and betahistine and the group treated with promethazine and betahistine with Epley maneuver

Comparing the speed and severity of improvement of peripheral vertigo in the group treated with promethazine and betahistine and the group treated with promethazine and betahistine with Epley maneuver

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20221108056446N14

Enrollment

100

Registered

2025-02-04

Start date

2025-03-05

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vertigo. Other peripheral vertigo

Interventions

Intervention 1: Intervention group: 25 mg of promethazine is injected intramuscularly in the dorsogluteal area and one 8 mg betahistine tablet is given orally to the patient. Intervention 2: Control g

Eligibility

Sex/Gender

All

Age

No minimum to 50 Years

Inclusion criteria

Inclusion criteria: Patients presenting with symptoms of peripheral vertigo Patients must consent to participate in the study.

Exclusion criteria

Exclusion criteria: Pregnant patients Cardiac conduction disorders Structural disorders of the cervical spine Patients with neck ligament and joint problems Cervical abnormalities Blood hemostasis disorders High international normalized ratio Persistent nausea and vomiting People with neurological impairments Sensory and motor disorders People with allergies to promethazine and betahistine Patients with central vertigo based on the workup

Design outcomes

Primary

Measure	Time frame
Vertigo. Timepoint: The speed of improvement in Vertigo is assessed based on the recorded times for each quarter and the Vertigo severity improvement table. If the patient does not improve within 2 hours after the above measures, treatment failure is confirmed and further medical treatments will be considered for the patients. Method of measurement: Numerical Rating Scale.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAmirbahador Boroumand

Esfahan University of Medical Sciences

ab.boroumand@med.mui.ac.ir+98 31 3620 2085

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026